Traws Pharma Inc. (TRAW)
NASDAQ: TRAW
· Real-Time Price · USD
1.44
-0.01 (-0.69%)
At close: May 01, 2025, 3:35 PM
-0.69% (1D)
| Bid | 1.42 |
| Market Cap | 7.31M |
| Revenue (ttm) | 226K |
| Net Income (ttm) | -166.52M |
| EPS (ttm) | -35.21 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.07 |
| Analyst | n/a |
| Ask | 1.46 |
| Volume | 25,058 |
| Avg. Volume (20D) | 77,145 |
| Open | 1.45 |
| Previous Close | 1.45 |
| Day's Range | 1.44 - 1.48 |
| 52-Week Range | 1.36 - 19.44 |
| Beta | 1.43 |
About TRAW
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor i...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 6
Stock Exchange NASDAQ
Ticker Symbol TRAW
Website https://www.trawspharma.com
Next Earnings Release
Traws Pharma Inc. is scheduled to release its earnings on May 14, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-4.17%
Traws Pharma FY24 EPS ($18.90) Up From ($22.57) Yo...
Unlock content with
Pro Subscription
1 month ago
-30.82%
Traws Pharma shares are trading lower. The company announced topline results from ferrets infected with H5N1 bird flu.
